# A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Source: https://onco.cc/trials/nct07205718/  
OnCo record `nct07205718` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TAK-188 in advanced solid tumours, run by Takeda, now recruiting.

## Summary

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors is a phase 1/2 interventional study registered as NCT07205718 by Takeda, with 223 participants planned, started 2025-11-19 and due to reach its primary completion in 2028-12-26. Interventions recorded: TAK-188.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07205718
- Phase: 1/2
- Setting: An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Takeda
- Enrolled: 223

## Sources

- ClinicalTrials.gov NCT07205718: https://clinicaltrials.gov/study/NCT07205718

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct07205718.json